P materials reporting results just moments ago. Adjusted loss of 10 cents per share. That was better than the 18 cents loss expected.Revenue just shy of estimates though, 53.6% million versus estimates of 54.9% million. MP noting it ceased all sales of products in China. Uh in part because of its deal with the Pentagon that resulted in no revenue recognized from rare earth concentrate during the quarter, driving the 15% decline in consolidated revenue year-over-year.Uh so keep that in mind with that topline ...

Expedia Group (NASDAQ: EXPE) delivered a clean beat on both earnings and revenue Thursday after the close, with adjusted EPS of $7.57 crushing the $6.95 consensus and gross bookings accelerating across both consumer and B2B channels. ...

out and that stock is tanking too. So Steve Kovak has those numbers. Steve.>> Yeah. Let me tell you why here, Morgan. It's not because of the quarter that they just reported.Those numbers look good. It's the further delay of Grand Theft Auto 6. It was supposed to come out of May 26 next year.They're now delaying that to November of 2026. This is the second delay for this game. And so you see shares reacting there.This does not affect their current fiscal year, but you can imagine that once we get guidance f ...

All right, AI data center stories. I think it's one for the ages, right. Which means it's always going to attract some doubters.Even rural towns are actually voting against having them there. I think it's a wasted opportunity for these towns. I mean, look behind me, folks.These stocks and that are priced in most of the names associated, you know, with the building this stuff. They're up huge, right. They're up significantly.However, as the story has evolved into a multi-t trillion dollar endeavor, more folk ...

Accessibility StatementSkip Navigation DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) ("Chesapeake Utilities" or the "Company") today announced financial results for the three and nine months ended September 30, 2025. Net income for the third quarter of 2025 was $19.4 million ($0.82 per share) compared to $17.5 million ($0.78 per share) in the third quarter of 2024. Excluding transaction and transition-related expenses associated with the acquisition and integration ...

Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial Bleeding SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the acquisition of San Diego based, IRRAS H ...

Max Levchin, CEO of Affirm (Pictured). Fed rate cuts and clearer U.S. credit guidance ease funding pressure and boost outlooks for BNPL players like Affirm.Getty ImagesThe Buy Now, Pay Later (BNPL) industry is at a pivotal moment as its largest U.S. pure-play, Affirm (AFRM), prepares to report fiscal first-quarter 2026 earnings today after the market close. Many investors are wondering whether this is the right time to buy or sell.Affirm reports fiscal Q1 2026 results today, covering July through September ...

As we head toward the close, we do want to bring in BTI's Jonathan Kinsky. Uh Jonathan, thank you so much for joining us here today. Obviously, we've had a lot of discussion about how AI is driving things lower today.You're looking at the 50-day moving average. What's so important about what you're seeing right now. >> Hey, Courtney.So, yeah, it's been a remarkable streak. We we have not touched the 50-day moving average in 145 trading days. That's the third longest streak since 1990. The second longest str ...

Well, all four major averages back in the red after yesterday's bounce. Tech once again the lagard as some recent highf flyers return to earth. Should investors view any pullback as a buying opportunity.Far Miller and Washington President CEO Michael Farre joins us. Michael, good to see you. Um, some of the highest valuation stocks in the market are also the biggest in tech.And so even beneath the index level, I wonder is there anywhere to hide. Won't the whole market get dragged down if there's a sentiment ...

Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday. ...